Speaking at Wednesday's C5 Congress on Biotech and Pharma Patenting in London, Michael McGraw, a partner from Fitzpatrick, Cella, Harper and Scinto in New York, considered the line that separates natural and man-made products.
Aliki Nichogiannopoulou, director of biotechnology at the European Patent Office, outlined best practices for patenting antibodies at the office while speaking at the 25th C5 Congress on Biotech and Pharma Patenting in London on Wednesday.
Orrick Herrington & Sutcliffe LLP has expanded its IP group and hired Grace Pan as partner.
Medical company Scion Biomedical Inc has launched a lawsuit accusing a senior employee of breaching trade secrets to file a patent for her new start-up company.
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.
The US District Court for the Northern District of California has dismissed biosimilar maker Sandoz’s motion for declaratory judgment that its etanercept product does not infringe biopharmaceutical company Amgen’s arthritis drug Enbrel.
A federal court has upheld a ruling that biotech company Illumina should pay rival Syntrix $115 million and an 8 percent running royalty rate for patent infringement.
The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.
The US Court of Appeals for the Federal Circuit affirmed on Tuesday that pharmaceutical company Pfizer can patent a DNA polynucleotide ahead of rival Sanofi-Aventis.
Novartis has urged the FDA to allow biosimilars to bear the same international nonproprietary names as their reference products.